Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The clinical and molecular significance associated with STING signaling in breast cancer.
Parkes EE, Humphries MP, Gilmore E, Sidi FA, Bingham V, Phyu SM, Craig S, Graham C, Miller J, Griffin D, Salto-Tellez M, Madden SF, Kennedy RD, Bakhoum SF, McQuaid S, Buckley NE. Parkes EE, et al. NPJ Breast Cancer. 2021 Jun 25;7(1):81. doi: 10.1038/s41523-021-00283-z. NPJ Breast Cancer. 2021. PMID: 34172750 Free PMC article.
Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer.
Mulligan JM, Hill LA, Deharo S, Irwin G, Boyle D, Keating KE, Raji OY, McDyer FA, O'Brien E, Bylesjo M, Quinn JE, Lindor NM, Mullan PB, James CR, Walker SM, Kerr P, James J, Davison TS, Proutski V, Salto-Tellez M, Johnston PG, Couch FJ, Paul Harkin D, Kennedy RD. Mulligan JM, et al. J Natl Cancer Inst. 2014 Jan;106(1):djt335. doi: 10.1093/jnci/djt335. J Natl Cancer Inst. 2014. PMID: 24402422 Free PMC article.
TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.
D'Costa ZC, Higgins C, Ong CW, Irwin GW, Boyle D, McArt DG, McCloskey K, Buckley NE, Crawford NT, Thiagarajan L, Murray JT, Kennedy RD, Mulligan KA, Harkin DP, Waugh DJ, Scott CJ, Salto-Tellez M, Williams R, Mullan PB. D'Costa ZC, et al. Oncotarget. 2014 Mar 30;5(6):1609-20. doi: 10.18632/oncotarget.1707. Oncotarget. 2014. PMID: 24742492 Free PMC article.
PICan: An integromics framework for dynamic cancer biomarker discovery.
McArt DG, Blayney JK, Boyle DP, Irwin GW, Moran M, Hutchinson RA, Bankhead P, Kieran D, Wang Y, Dunne PD, Kennedy RD, Mullan PB, Harkin DP, Catherwood MA, James JA, Salto-Tellez M, Hamilton PW. McArt DG, et al. Mol Oncol. 2015 Jun;9(6):1234-40. doi: 10.1016/j.molonc.2015.02.002. Epub 2015 Mar 4. Mol Oncol. 2015. PMID: 25814194 Free PMC article.
Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility.
Alvi MA, McArt DG, Kelly P, Fuchs MA, Alderdice M, McCabe CM, Bingham V, McGready C, Tripathi S, Emmert-Streib F, Loughrey MB, McQuaid S, Maxwell P, Hamilton PW, Turkington R, James JA, Wilson RH, Salto-Tellez M. Alvi MA, et al. Oncotarget. 2015 Aug 28;6(25):20863-74. doi: 10.18632/oncotarget.4576. Oncotarget. 2015. PMID: 26315110 Free PMC article.
321 results